TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06187077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DHA-Enhanced FAITH! App
Description: This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FAITH! App
Description: This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
Study: NCT06394245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle exercises
Description: The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
Study: NCT06650878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desarda
Description: This technique prevent from using a mesh to surgical repair of a inguinal hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein
Description: This technique implies using a mesh to surgical repair of a inguinal hernia
Study: NCT05384873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control dietary intervention
Description: Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
Study: NCT05505487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated care model
Description: The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 8 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 8 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fH1 8 ug
Description: 2 administrations at 3-week intervals.
Study: NCT05707364

Intervention type: BEHAVIORAL
Intervention: Pre-visit Lab Workflow
Description: 1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys.
Study: NCT05619627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: Patients will receive inhalational anesthetic to provide general anesthesia for undergoing MRI
Study: NCT06263504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: at correcting malocclusions or restoring the integrity of the dentition
Description: Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
Description: ): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
Study: NCT05852964

Intervention type: GENETIC
Intervention: Molecular Immunology , gene expressions
Description: Expression levels of inflammatory and anti-inflammatory genes

Intervention type: GENETIC
Intervention: Molecular Immunology , gene expressions
Description: Expression levels of inflammatory and anti-inflammatory genes
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 2.5 ug
Description: 2 administrations at 3-week intervals.
Study: NCT05254964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Description: Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
Study: NCT05954221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red cell lysis buffer (RCLB) application
Description: The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional processing
Description: The tissue is fixed with 10% formalin.
Study: NCT06103266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 2.5 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 2.5 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 5 ug
Description: 2 administrations at 3-week intervals.
Study: NCT04201444

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient group
Description: Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Remission control group
Description: Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral surrenalectomy control group
Description: Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
Study: NCT06460064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 5 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 5 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 10 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 10 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP-0546LP 10 ug
Description: 2 administrations at 3-week intervals.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 administrations at 3-week intervals.
Study: NCT04736966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 30mg
Description: 30mg of Guselkumab administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 70mg
Description: 70mg of Guselkumab administered by subcutaneous injection
Study: NCT05485285

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study: NCT06118957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
Study: NCT05305963

Intervention type: RADIATION
Intervention: Mammogram
Description: mammogram

Intervention type: RADIATION
Intervention: Mammogram
Description: mammogram
Study: NCT04736966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100mg
Description: 100mg of Guselkumab administered by subcutaneous injection
Study: NCT05535829

Intervention type: OTHER
Intervention: Laboratory analysis of samples
Description: Laboratory analysis of samples
Study: NCT06077942

Intervention type: DEVICE
Intervention: FX Artificial Shoulder Prosthesis
Description: Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
Study: NCT06130592

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound muscle imaging technique
Description: ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound muscle imaging technique
Description: ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
Study: NCT05175742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B
Description: Sterile solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B
Description: Sterile solution for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 vaccine
Description: Sterile solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05725512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to prednisolone tablets
Study: NCT05013476

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly handheld ultrasound machine
Description: Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly handheld ultrasound machine
Description: Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
Study: NCT05482841

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound score
Description: To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
Study: NCT04873323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Single dose of moxifloxacin 400 mg in the morning under fasting in each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of TS-142 placebo in the morning under fasting in each period
Study: NCT06077474

Intervention type: OTHER
Intervention: Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)
Description: Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
Study: NCT05549505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg tablet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of breast tumor
Description: Participants will have surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection of breast tumor
Description: Participants will have surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
Study: NCT06582420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard trauma care
Description: Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
Study: NCT06582862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will do aerobic and anaerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will do aerobic and anaerobic exercise
Study: NCT06582121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: An overnight sleep study
Study: NCT06581107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation
Description: During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are recorded. The performance of the research device is evaluated by the radiologists. Postoperative complications of the participants are recorded 7±1 days postoperatively/on the day of discharge based on the postoperative CT scan (whichever comes first).
Study: NCT05768035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic T cell progenitors, cultured ex-vivo
Description: Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
Study: NCT06260553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab and metronomic oral vinorelbine
Description: tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
Study: NCT06486415

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum BHCG testing
Description: Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum BHCG testing
Description: Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
Study: NCT05673070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ritual Epre Multivitamin-mineral supplement
Description: The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control MVI
Description: The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
Study: NCT06230939

Intervention type: OTHER
Intervention: Examination
Description: Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method.
Study: NCT05378737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8006 for Injection
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8006 for Injection
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8006 for Injection
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8006 for Injection
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8006 for Injection
Description: Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.